Evaluation of circulating IGF-I and IGFBP-3 as biomarkers for tumors in dogs
- Author:
Doo-Won SONG
1
;
Woong-Bin RO
;
Jung-Hyang SUR
;
Byung-Joon SEUNG
;
Hyun-Min KANG
;
Jong-Won KIM
;
See-Hyoung PARK
;
Hee-Myung PARK
Author Information
- Publication Type:Original Article
- From:Journal of Veterinary Science 2021;22(6):e77-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Serum-based parameters are considered non-invasive biomarkers for cancer detection. In human studies, insulin-like growth factor-I and II (IGF-I and IGF-II) and insulin-like growth factor binding protein-3 (IGFBP-3) are useful as diagnostic or prognostic markers and potential therapeutic targets.
Objectives:This study examined the diagnostic utility of circulating IGF-I, IGF-II, and IGFBP-3 levels in healthy dogs and dogs with tumors.
Methods:The serum concentrations of these biomarkers in 86 dogs with tumors were compared with those in 30 healthy dogs using an enzyme-linked immunosorbent assay (ELISA).
Results:The ELISA results showed no difference between healthy dogs and dogs with tumors in the serum IGF-II concentrations. On the other hand, there was a significant difference in the circulating IGF-I and IGFBP-3 levels between healthy dogs and dogs with tumors. The concentrations of serum IGF-I (median [interquartile range], 103.4 [59.5–175] ng/mL) in dogs with epithelial tumors were higher than those (58.4 ng/mL [43.5–79.9]) in healthy dogs.Thus, the concentrations of serum IGFBP-3 (43.4 ng/mL [33.2–57.2]) in dogs with malignant mesenchymal tumors were lower than those (60.8 ng/mL [47.6–70.5]) in healthy dogs.
Conclusions:The serum IGF-I and IGFBP-3 levels can be used as diagnostic biomarkers in dogs with tumors.
